All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inactivated SARS-CoV-2 virus
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
Chinese company Sinovac Biotech has obtained approval for its Covid-19 vaccine, CoronaVac, from Thailand’s Food and Drug Administration (FDA) for local emergency use prior to the launch of a vaccination programme in the country.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SARS-CoV-2 inactivated vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2021
Details:
Chinese regulator National Medical Products Administration has granted approval to Sinovac Biotech’s unit for its Covid-19 vaccine, CoronaVac. Sinovac’s vaccine became the second one to receive approval in China, Reuters reported.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inactivated SARS-CoV-2 virus
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2021
Details:
Brazil’s health regulator Anvisa on Friday approved a second emergency use request of China’s CoronaVac vaccine, which will allow for the distribution of 4.8 million new doses that were partly manufactured in Brazil.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inactivated SARS-CoV-2 virus
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
Sinovac’s CoronaVac vaccine was 78% effective in preventing mild cases of Covid-19 and 100% effective against severe and moderate infections.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inactivated Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2021
Details:
The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, Chinese equivalent of FDA.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 23-Valent Pneumococcal Polysaccharide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2020
Details:
China National Medical Products Administration (NMPA) has approved and issued a Product license for the Company’s 23-Valent Pneumococcal Polysaccharide (“PPV”) Vaccine to prevent the infection by streptococcus pneumonia in adults and children ages 2 years old and above.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inactivated Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Beijing Institute of Biological Product
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
MOHAP, in collaboration with Department of Health Abu Dhabi, DOH, has reviewed Sinopharm CNBG’s interim analysis of the phase III trials, which shows Beijing Institute of Biological Product’s inactivated vaccine to have 86 percent efficacy against COVID-19 infection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoronaVac
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
The phase III clinical trial seeks to test efficacy and safety of CoronaVac in Turkey and aims to be a pivotal study to support the licensure of this product.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoronaVac
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2020
Details:
Phase 3 clinical trials of a potential COVID-19 vaccine developed by China’s Sinovac Biotech Ltd have shown promising results and it may be available to Brazilians as early as December.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lianhua Qingwen
Therapeutic Area: Infections and Infectious Diseases Product Name: KT07
Highest Development Status: Approved Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2020
Details:
Lianhua Qingwen Capsules was approved to be registered as a drug to treat symptoms like fever, cough, debilitation, sore muscles, nasal obstruction, runny nose, headaches, a dry and sore throat, shortness of breath, and a red tongue caused by viral diseases including COVID-19.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
